Program

* Please check the time table for English sessions.

Dates

Onsite:	March 16 (Thu) – 18 (Sat), 2023 (Some sessions will be live streamed.)

On-demand streaming: April 3 (Mon) – 28 (Fri) 5:00 pm, 2023

*: Live streaming and on-demand streaming are only available for some sessions.
- Live streaming: Room 1 and 7
- On-demand streaming: Presidential Session
*: Live streaming and on-demand streaming services are available on JSMO 2023’s virtual session website. Detailed information about the website will be posted on the official website of the Meeting immediately prior to the commencement of the Meeting.

Special Lecture
Anniversary Lecture
Presidential Session
Highlight of the Day
Presidential Symposium
Symposium
ASCO/JSMO Joint Symposium
ESMO/JSMO Joint Symposium
Asia-Pacific/JSMO Joint Symposium
DIA/JSMO Joint Symposium
SIOG/JSMO Joint Symposium
Joint Symposium
Committee Program
Educational Lecture

Special Lecture

Simultaneous interpretation

March 17 (Fri), 10:15–11:15 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Chair:	Eishi Baba	(Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University)

Balancing Architectural Works and Social Contributions
	Shigeru Ban	(SHIGERU BAN ARCHITECTS)

CV: Born in Tokyo in 1957. Graduated from the Cooper Union. Started working for Arata Isozaki & Associates in 1982. Founded Shigeru Ban Architects in 1985. Became consultant to the United Nations High Commissioner for Refugees (UNHCR) in 1995. Established the NGO, Voluntary Architects' Network (VAN) in the same year to support disaster relief. Selected works include Centre Pompidou- Metz, Oita Prefecture Art Museum, Mt. Fuji World Heritage Centre, Shizuoka, Musical Complex of La Seine Musicale, and Swatch Omega Headquarters. Recipient of multiple awards, including Grande Médaille d’or de l’Académie d’architecture, France (2004), Grand Prize of AIJ (2009) , le grade d’officier for L’Ordre des Arts et des Lettres, France (2010), Auguste Perret Prize (2011), Art Prize from the Japanese Agency for Cultural Affairs (2012), le grade de commandeur for L’Ordre des Arts et des Lettres, France (2014), Pritzker Architecture Prize (2014), Medal of Honor with Purple Ribbon, Japan (2017) , Mother Teresa Social Justice Award (2017) and Princess of Asturias Award for Concord (2022). An ambassador among "distinguished thinkers and practitioners" for the New European Bauhaus high-level roundtable (2021). Currently Professor at Keio University.

Anniversary Lecture

Simultaneous interpretation

March 17 (Fri), 14:00–15:10 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Chair:	Chikashi Ishioka	(President, Board of Directors, JSMO)

Looking Back on Half a Century of Research Thoughts on Basic Research
	Yoshinori Ohsumi	(Tokyo Institute of Technology, Cell Biology Center, Institute of Innovative Research Honorary Professor)
	*The Nobel Prize in Physiology or Medicine in 2016.

Presidential Session

Presidential Session 1 (Lung cancer/Thoracic Cancer)

March 16 (Thu) 15:20-17:20 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Yuichiro Ohe	(Department of Thoracic Oncology, National Cancer Center Hospital)
	Peters Solange	(Department of Oncology, Lausanne University)

Discussant:
PS1-1	Randomized P-II/III trial of nivolumab (NIV) vs NIV+docetaxel for previously treated advanced/recurrent NSCLC: TORG1630
	Naoki Furuya	(Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine)
	Shun Lu	((ISC(Shanghai Chest Hospital))
PS1-2	First Report of Cohort 3 and Mature Survival Data From the U31402-A-U102 Study of HER3‑DXd in EGFR-Mutated NSCLC
	Hidetoshi Hayashi	(Department of Medical Oncology, Kindai University, Osaka, Japan)
Discussant:
	Byoung Chul Cho	(Yonsei University)
PS1-3	Final results of phase III study of pemetrexed/cisplatin vs. vinorelbine/cisplatin for resected non-squamous NSCLC
	Koji Yamazaki	(Department of Thoracic Surgery, National Hospital Organization Kyushu Medical Center)
Discussant:
	Satoru Miura	(Department of Internal Medicine, Niigata Cancer Center Hospital, Japan)
PS1-4	Adjuvant osimertinib in resected EGFR-mutated stage II–IIIA NSCLC: ADAURA Japan subgroup analysis
	Hirotsugu Kenmotsu	(Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan)
Discussant:
	Kentaro Tanaka	(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)
PS1-5	Sotorasib versus Docetaxel for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation: CodeBreaK 200 Phase 3 Study
	Isamu Okamoto	(Department of Respiratory Medicine, Kyushu University Hospital, Fukuoka, Japan)
Discussant:
	Kei Kunimasa	(Department of Thoracic Oncology, Osaka International Cancer Institute)

Presidential Session 2 (Breast Cancer)

March 17 (Fri), 16:25-18:05 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Hiroji Iwata	(Aichi Cancer Center Hospital)
	Sandra M Swain	(Georgetown University)

Discussant:
PS2-1	Overall survival results from the phase 3 TROPiCS-02 study of sacituzumab govitecan vs chemotherapy in HR+/HER2- mBC
	Hope S. Rugo	(Department of Medicine, University of California-San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA)
	Naoki Niikura	(Department of Breast Oncology, Tokai University School of Medicine)
PS2-2	T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: results of DESTINY-Breast04
	Junji Tsurutani	(Advanced Cancer Translational Research Institute at Showa University)
Discussant:
	Tatsunori Shimoi	(Department of Medical Oncology, National Cancer Center Hospital)
PS2-3	T-DXd vs treatment of physician's choice in HER2+ mBC previously treated with T-DM1: primary results of DESTINY-Breast02
	Toshimi Takano	(The Cancer Institute Hospital of JFCR, Tokyo, Japan)
Discussant:
	Yen-Sheng Lu	(ISC(National Taiwan University College of Medicine))
PS2-4	Phase 1/2 Study of HER3-DXd in HER3-Expressing Metastatic Breast Cancer:Subgroup Analysis by HER2 Expression
	Hiroji Iwata	(Aichi Cancer Center Hospital, Nagoya, Japan)
Discussant:
	Masahiro Takada	(Department of Breast Surgery, Kyoto University Graduate School of Medicine)

Presidential Session 3 (Miscellaneous)

March 17 (Fri), 8:20-10:20 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Session Information

Chairs:	Chikashi Ishioka	(Department of Clinical Oncology, Tohoku University Graduate School of Medicine)
	Jorge E Cortes	(Geogia Cancer Center)

Discussant:
PS3-1	MOMENTUM: Phase 3 Study of Momelotinib vs Danazol in Symptomatic and Anemic Myelofibrosis Patients post-JAK Inhibition
	Jun Kawashima	(Sierra Oncology, a GSK company, San Mateo, California, United States of America)
	Kazuya Shimoda	(Hematology, Diabetes, and Endocrinology, University of Miyazaki)
PS3-2	Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma (R/RMCL) in ZUMA-2: Durable Responder Analysis
	Javier Munoz	(Banner MD Anderson Cancer Center, Gilbert, AZ, USA)
Discussant:
	Won Seog Kim	(Samsung Medical Center)
PS3-3	Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412
	Makoto Tahara	(Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan)
Discussant:
	Hisham Mehanna	(University of Birmingham IISC)
PS3-4	APOBEC signature and the immunotherapy response in pan-cancer
	Ya-Hsuan Chang	(Institute of Statistical Science, Academia Sinica, Taipei, Taiwan)
Discussant:
	Yasuhiro Koh	(Center for Biomedical Sciences/Internal Medicine III, Wakayama Medical University)
PS3-5	Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2
	Chigusa Morizane	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
Discussant:
	Li-Tzong Chen	(National Institute of Cancer Research, Taiwan)

Presidential Session 4 (Gastrointestinal Cancer)

March 18 (Sat), 9:45-11:45 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Eishi Baba	(Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University)
	Zev A Wainberg	(UCLA Medical Center)

Discussant:
PS4-1	Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
	Akira Ooki	(Department of Gastroenterological chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)
	Chih-Hung Hsu	(National Taiwan University)
PS4-2	PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer
	Andrea Cercek	(Memorial Sloan Kettering Cancer Center)
Discussant:
	Shin Takahashi	(Chemotherapy Center, Sendai Kousei Hospital)
PS4-3	Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: the DEEPER trial (JACCRO CC-13)
	Akihito Tsuji	(Department of Clinical Oncology, Faculty of Medicine, Kagawa University)
Discussant:
	Tae Won Kim	(Asan Medical Center)
PS4-4	Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM
	Kei Muro	(Department of Clinical Oncology, Aichi Cancer Center Hospital)
Discussant:
	Taroh Satoh	(Palliative Care Center, Osaka University Hospital)
PS4-5	Efficacy and safety of fruquintinib in Japanese patients with refractory metastatic colorectal cancer from FRESCO-2
	Daisuke Kotani	(Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan)
Discussant:
	Kentaro Yamazaki	(Division of Gastrointestinal Oncology, Shizuoka Cancer Center)

Highlight of the Day

Highlight of the Day 1

March 17 (Fri), 8:30-10:00
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Seiji Yano	(Department of Respiratory Medicine, Faculty of Medicine, Kanazawa University)
	Eishi Baba	(Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University)

HoD1-1	Patient Advocacy / Survivorship
	Hisakazu Nishimori	(Department of Hematology and Oncology, Okayama University Hospital)
HoD1-2	Breast Cancer
	Toshimi Takano	(The Cancer Institute Hospital of JFCR)
HoD1-3	Gynecologic Cancer
	Noriyuki Katsumata	(Department Medical Oncology, Nippon Medical School Musashikosugi Hospital)
HoD1-4	Palliative Care / Symptom Management
	Atsushi Sato	(Hirosaki University Graduate School of Medicine, Department of Medical Oncology)
HoD1-5	Head and Neck Cancer
	Naomi Kiyota	(Kobe University Hospital Cancer Center)

Highlight of the Day 2

March 18 (Sat), 8:30-9:40
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Seiji Yano	(Department of Respiratory Medicine, Faculty of Medicine, Kanazawa University)
	Hiroji Iwata	(Aichi Cancer Center Hospital)

HoD2-1	Hepatobiliary / Pancreatic Cancer
	Takuji Okusaka	(National Cancer Center Hospital)
HoD2-2	Lung Cancer / Thoracic Cancer
	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital)
HoD2-3	Translational Research / Clinical Pharmacology
	Yasuhiro Koh	(Center for Biomedical Sciences, Wakayama Medical University)
HoD2-4	Clinical Trial Facilitation Program
	Kenichi Nakamura	(Department of International Clinical Development, National Cancer Center Hospital)

Highlight of the Day 3

March 18 (Sat), 14:50-16:30
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Hiroji Iwata	(Aichi Cancer Center Hospital)
	Eishi Baba	(Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University)

HoD3-1	Rare Cancer / Cancer of Unknown Primary
	Takayasu Kurata	(Department of Thoracic Oncology, Kansai Medical University)
HoD3-2	Hematorogic Malignancies
	Eisei Kondo	(Depertment of Hematology, Kawasaki Medical School)
HoD3-3	Genitourinary Cancer
	Yuji Miura	(Department of Medical Oncology, Toranomon Hospital)
HoD3-4	Multidisciplinary Team Program
	Taito Esaki	(National Hospital Organization Kyushu Cancer Center, Clinical Research Institute)
HoD3-5	Gastrointestinal Canter
	Ayumu Hosokawa	(Department of Clinical Oncology, University of Miyazaki Hospital)
HoD3-6	Cross-sectional Program
	Chihiro Kondoh	(Department of Medical Oncology, National Cancer Center Hospital East)

Presidential Symposium

Presidential Symposium 1
Current and Future of Financial Toxicity

March 16 (Thu), 10:10–11:40 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Session Information

Chairs:	Kei Muro	(Department of Clinical Oncology, Aichi Cancer Center Hospital)
	Fumi Hattori	(Bridge - Support Network for Working During Treatment (General Incorporated Association))

Discussant:
PSY1-1	Financial Toxicity Awareness Project (FT-01)
	Kazunori Honda	(Department of Clinical Oncology, Aichi Cancer Center)
PSY1-2	Evaluating the Cost-Effectiveness and Value of Anticancer Drugs
	Ataru Igarashi	(Unit of Public Health and Preventive Medicine Yokohama City University School of Medicine)
PSY1-3	Financial Toxicity of Cancer Treatment: From Measurement to Solutions
	Bishal Gyawali	(Department of Oncology, Queen's University)
	Yusuke Kajimoto	(Graduate school of Pharmaceutical Sciences, The University of Tokyo)
	Hiroki Shirato	(Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University)
	Mami Koga	(Non-Profit Organization CancerNet Japan)

Presidential Symposium 2
The Present and Future of Drug Development for Asian Rare Cancers in the World

March 16 (Thu), 14:00–15:30 (JST)
Room3 (MARINE MESSE FUKUOKA Hall A 2F Large Meeting Room)

Session Information

Chairs:	Nariaki Matsuura	(Osaka International Cancer Institute)
	Yoshiyuki Majima	(Rare Cancers Japan)

PSY2-1	The Power of Patient Engagement in Drug Development for Rare Cancers: Rationale for Research Co-Creation, and Mapping the Current Landscape
	Kathy Rose Oliver	(International Brain Tumour Alliance (IBTA))
PSY2-2	Unmet Needs of Rare Cancers Patients in Japan
	Hiroyuki Onishi	(Rare Cancers Japan)
PSY2-3	Current Status and Issues of Drug Development to Enable Earlier Patient Access for Rare Cancer in Japan
	Yuji Kashitani	(Takeda Pharmaceutical Company Limited)
PSY2-4	PMDA's Efforts in Addressing New Drug Needs for Rare Cancers in Asia
	Yasuhiro Fujiwara	(Pharmaceuticals and Medical Devices Agency)

Presidential Symposium 3
Future perspectives of emerging therapies for gastroesophageal adenocarcinoma

English Session

March 16 (Thu), 14:00–15:30 (JST)
Room9 (Fukuoka International Congress Center 2F 203+204)

Session Information

Chairs:	Yelena Janjigian	(Memorial Sloan Kettering Cancer Center)
	Kohei Shitara	(National Cancer Center Hospital East)

PSY3-1	HER2 targeted therapy
	Yelena Janjigian	(Memorial Sloan Kettering Cancer Center)
PSY3-2	Perspective on emerging biomarker-driven therapies in Gastric Cancer, FGFR2 and Beyond
	Zev A. Wainberg	(Ronald Reagan UCLA Medical Center,UCLA Medical Center, Santa Monica)
PSY3-3	Claudin 18.2 targeted therapy for gastric and GEJ adenocarcinoma
	Kohei Shitara	(National Cancer Center Hospital East)
PSY3-4	EGFR inhibition for gastroesophageal adenocarcinoma
	Daisuke Kotani	(Department of Gastrointestinal Oncology, National Cancer Center Hospital East)

Presidential Symposium 4

March 16 (Thu), 14:00–15:30 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Jiichiro Sasaki	(Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine)
	Kiyotaka Watanabe	(Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University)

PSY4-1	Education and Training for Cancer Counselors in Cancer Information and Support Centers
	TakayamaTomoko	(National Cancer Center Institute for Cancer Control Cancer Information Service Division)
PSY4-2	The Cancer Care Network Navigator System certified by JSCO
	Jiichiro Sasaki	(Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine)
PSY4-3	The activities of support groups in designated cancer hospitals
	Asao Ogawa	(Division of Psycho-Oncology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)
PSY4-4	Peer Supporter Training Program of Cancer Patients Support Organization
	Chizuko Sakashita	(Devision of Hematology, Tokyo Medical and Dental University)
PSY4-5	Educational projects in Cancer Net Japan (navigator/coordinator)
	Mami Koga	(CancerNet Japan, Non-profit Organization)
PSY4-6	Aiming for Better Peer Support ~Training Issues and Future Possibilities~
	Yoko Matsumoto	(NPO Ehime Cancer Support Orange-nokai)

Presidential Symposium 5
Career empowerment plans in JSMO

March 18 (Sat), 14:00–15:30 (JST)
Room3 (MARINE MESSE FUKUOKA Hall A 2F Large Meeting Room)

Session Information

Chairs:	Takako Nakajima	(Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
	Ikuko Takahashi	(Human Resources Department Taiho Pharmaceutical Co., Ltd.)

Discussant:
PSY5-1	Career Counseling Café at Japanese Society of Clinical Oncology (JSMO)
	Chihiro Kondoh	(National Cancer Center Hospital East Department of Medical Oncology)
PSY5-2	Introduction of Career Support Guidebook and Career Counseling Caf?
	Teruhisa Azuma	(Department of General Internal Medicine, Nara Prefecture General Medical Center)
PSY5-3	Medical staff can also use the Career Consultation Café!
	Shuichi Nawata	(Department of pharmacy, Showa University Northern Yokohama Hospital / Showa University School of Pharmacy Department of Hospital Pharmaceutics)
	Kyoko Kato	(National Hospital Organization Nagoya Medical Center, Department of Medical Oncology)
	Jumpei Tokumaru	(AstraZeneca K.K. Oncology Medical)
	Yui Tsunokuma	(Osaka Red Cross Hospital)

Symposium

Symposium 1
Future perspectives of molecular targets for GI cancer

English Session

March 16 (Thu), 8:30–10:00 (JST)
Room1 (MARINE MESSE FUKUOKA Hall A 1F Multi-purpose Exhibition Hall)

Summary: Molecular targets, not only already approved in GI cancer, but potential with promissing non-clinical data will be discussed. Clinical platforms giving matched therapy more effectively will be also discussed.

Session Information

Chairs:	RHA SUN YOUNG	(Yonsei Cancer Center, Yonsei University Health System)
	Hiromichi Ebi	(Division of Molecular Therapeutics, Aichi Cancer Center Research Institute)

SY1-1	Future perspectives of molecular targets for GI cancer:Future of novel targets in advanced gastric cancer
	Sun Young Rha	(Yonsei Cancer Center, Yonsei University Health System)
SY1-2	Potential molecular targets for colorectal cancer based on recent genome-wide molecular classification
	Osamu Kikuchi	(Clinical Oncology, Kyoto University Hospital)
SY1-3	Investigational immunotherapies in gastrointestinal cancer
	Akihito Kawazoe	(Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital East)
SY1-4	The Whack-A-Mole for Cancer Therapy:Combination Approach for Precision Oncology
	Shumei Kato	(UC San Diego Moores Cancer Center)

Symposium 2
Part1:Overview of JSMO Cancer Immunotherapy Guideline, Third Edition
Evolution of investigator-initiated registration-directed trials under J-GCP

March 16 (Thu), 8:30–10:00 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Session Information

Chairs:	Kosei Hasegawa	(Department of Gynecologic Oncology, Saitama Medical University International Medical Center)
	Koji Takeda	(West Japan Oncology Group)

SY2-1	Investigator-initiated study for lung cancer in Japan
	Hirotsugu Kenmotsu	(Division of Thoracic Oncology, Shizuoka Cancer Center)
SY2-2	Investigator-initiated clinical trials in breast cancer Current Status and Issues
	Fumikata Hara	(Department of Breast medical oncology, Cancer Institute Hospital)
SY2-3	Investigator initiated clinical trials in the Hepatobiliary and Pancreatic tumor.
	Makoto Ueno	(Department of Gastroenterology, Kanagawa Cancer Center)
SY2-4	Achievements and prospects of investigator-initiated clinical trials for rare cancers
	Kazuki Sudo	(Department of Medical Oncology, National Cancer Center Hospital)

Symposium 3
Next cancer immunotherapy

English Session

March 16 (Thu), 10:10–11:40 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Summary: Immune checkpoint inhibitors (ICIs) such as monoclonal antibodies against PD-1/PD-L1 have been approved in the treatment for various types of cancer including melanoma, lung cancer, and head-and-neck cancer, leading to a paradigm shift in cancer therapy. However, their efficacies are unsatisfactory with response rate of 20%-30% by monotherapies. To increase efficacy, several combination therapies have been tried or already approved. In this session, from basic and translational insights, some experts will give lectures on next immuno-oncology (IO) treatments beyond PD-1 blockade.

Session Information

Chairs:	Yosuke Togashi	(Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
	Zarour Hassane	(University of Pittsburgh)

SY3-1	Next cancer immunotherapy beyond PD-1 blockade
	Yosuke Togashi	(Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
SY3-2	Molecular imaging unveils realistic features of T cell activation signaling via TCRs, costimulatory and coinhibitory receptors and CARs
	Tadashi Yokosuka	(Department of Immunology, Tokyo Medical University)
SY3-3	Elucidation of the functional ligand of LAG-3 in the suppression of autoimmunity and anti-cancer immunity
	Taku Okazaki	(Laboratory of Molecular Immunology Institute for Quantitative Biosciences The University of Tokyo)
SY3-4	TIGIT blockade therapy from basic insights to clinics
	Zarour Hassane	(University of Pittsburgh)

Symposium 4
Future direction of digital health apps and SaMD (software as medical device)

March 16 (Thu), 15:50–17:20 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Session Information

Chairs:	Akira Inoue	(Department of Palliative Medicine, Tohoku University School of Medicine)
	Seiichiro Yamamoto	(Shizuoka Graduate University of Public Health)

SY4-1	Overview
	Shogo Nomura	(Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo)
SY4-2	Trends and Examples of Digital Therapeutics in Oncology
	Kohta Satake	(Japanese Red Cross Medical Center, Department of Respiratory Medicine, CureApp, Inc. President and CEO)
SY4-3	Development and Future Vision of an electronic patient-reported outcome measure (ePROM) system in Oncology Practice
	Naruto Taira	(Kawasaki medical school)
SY4-4	Medical Application in Oncology
	Yasushi Goto	(National Cancer Center Hospital Department of Thoracic Oncology)
SY4-5	Regulatory requirements for preventive and therapeutic apps as a medical device
	Yuzuru Okazaki	(Pharmaceuticals and Medical Devices Agency)

Symposium 5
Treatment for advanced or recurrent cervical cancer: up to date and controversial

English Session

March 16 (Thu), 8:30–10:00 (JST)
Room3 (MARINE MESSE FUKUOKA Hall A 2F Large Meeting Room)

Summary: Issues of the treatment for advanced or recurrent cervical cancer including surgery, radiotherapy, chemotherapy, new targeted drugs, or immune-check point inhibitor will be discussed.

Session Information

Chairs:	Hideaki Yahata	(Department of Gynecology and Obstetrics Graduate School of Medical Sciences, Kyushu University)
	Krishnansu Sujata Tewari	(Professor, Division of Gynecologic Oncology, Obstetrics & Gynecology School of Medicine at the University of California, Irvine)

SY5-1	Current Management of Recurrent/Metastatic Cervical Cancer
	Krishnansu Sujata Tewari	(University of California, Irvine Medical Center)
SY5-2	Current controversies in systemic therapies for advanced or recurrent cervical cancer
	Jack Junjie Chan	(Department of Breast & Gynaecology, Division of Medical Oncology, National Cancer Centre Singapore, Singapore / Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore)
SY5-3	Controversies in the surgical treatment for local recurrent cervical cancer
	Munetaka Takekuma	(Shizuoka Cancer Center)
SY5-4	Current situation of advanced and recurrent cervical cancer treatment in Thailand
	Kittipat Charoenkwan	(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University)
SY5-5	Clinical trials for advanced or recurrent cervical cancer
	Jae-Weon Kim	(Department of Obstetrics and Gynecology, Seoul National University)
SY5-6	Is there a role for immune - checkpoint inhibitor with advanced or recurrent cervical cancer?
	Jing Li	(Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China)

Symposium 6
Considering optimal treatment of premenopausal breast cancer

English Session

March 16 (Thu), 15:40–17:10 (JST)
Room3 (MARINE MESSE FUKUOKA Hall A 2F Large Meeting Room)

Summary: Premenopausal breast cancer is especially common in Asia, and we must take the initiative in solving this issue. Premenopausal breast cancer has various issues such as tumor and host biology, patient's life style, and individual values. In this session, we will have an overview of the various problems of premenopausal breast cancer, followed by a breakdown of the issues regarding fertility, survivorship, hormone therapy, and chemotherapy, and finally a comprehensive discussion.

Session Information

Chairs:	Chikako Shimizu	(Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
	Fumikata Hara	(Cancer Institute Hospital of JFCR Department of Breast Medical Oncology)

SY6-1	Optimal therapy concepts in premenopausal patients with HR+ HER2- early breast cancer
	Nadia Harbeck	(Breast Center, LMU University Hospital, Munich, Germany)
SY6-2	Treatment and survivorship for premenopausal women with breast cancer
	Makiko Ono	(Department of Medical Oncology, Cancer Institute Hospital of JFCR)
SY6-3	Endocrine therapy for premenopausal patients with breast cancer: Current treatment strategy and challenges
	Yukinori Ozaki	(Department of Breast Medical Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
SY6-4	The sensitivity to chemotherapy for breast cancer in premenopausal women: differences from postmenopausal women and reasons for the differences
	Tetsuhiro Yoshinami	(Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)

Symposium 7
Update to Strategies for the Treatment of NSCLC with Driver Gene Mutation

English Session

March 16 (Thu), 14:00–15:30 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Summary: Starting with EGFR mutated NSCLC, therapeutic strategies for NSCLC with oncogenic driver mutation have progressed over the years. Recently, development strategies have been multifaceted, including adjuvant and post-radiotherapy chemotherapy, combinations of cytotoxic chemotherapy and molecularly targeted therapies, and ADC drugs. In addition, the development of molecularly targeted therapies for NSCLC with rare driver mutations, such as ALK and ROS-1, has been remarkable. The status of these complex NSCLC with driver mutation treatment strategies as of 2023 will be discussed in the sections.

Session Information

Chairs:	Janne Pasi	(Dana Farber Cancer Institute)
	Isamu Okamoto	(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

SY7-1	Treatment strategy for MSCLC with rare driver mutations
	Hochmair Maximilian	(Respiratory Oncology Unit Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf)
SY7-2	Novel strategies for the treatment of EGFR mutant Non-Small Cell Lung Cancer
	Pasi Janne	(Dana Farber Cancer Institute)
SY7-3	Combinational treatment with molecular-targeted therapy plus cytotoxic chemotherapy in non-small cell lung cancer with driver mutation
	Hiroaki Akamatsu	(Internal Medicine III, Wakayama Medical University)
SY7-4	Local therapies with molecular targeted drugs
	Hirotsugu Kenmotsu	(Division of Thoracic Oncology, Shizuoka Cancer Center)
SY7-5	ADC for patients with oncogenic alterations
	Yasushi Goto	(Thoracic Oncology, National Cancer Center)

Symposium 8
Reviewing the role of proper use of genetic alteration specific/tumor - agnostic driven anti-cancer drugs and cancer genomic panel testings

March 16 (Thu), 8:30–10:00 (JST)
Room8 (Fukuoka International Congress Center 2F 201+202)

Session Information

Chairs:	Kenji Tamura	(Department of Medical Oncology, Shimane University Hospital)
	Yoichi Naito	(General Internal Medicine, National Cancer Center Hospital East)

Discussant:
SY8-KL	Use of multicompanion and CGP testing
	Masayuki Takeda	(Department of Cancer Genomics and Medical Oncology, Nara Medical University)
	Kuniko Sunami	(Department of Laboratory Medicine, National Cancer Center Hospital)
	Sakai Kazuko	(Department of Genome Biology, Kindai University Faculty of Medicine)
	Shinichi Toyooka	(Department of Thoracic, Breast and Endocrine Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
	Koshi Mimori	(Department of Surgery, Kyushu University Beppu Hospital)
	Hideaki Bando	(Department of Gastroenterology and Gastrointestinal Oncology)

Symposium 9
Individualizing Adjuvant Therapy in patients with HER2-negative breast cancer

English Session

March 16 (Thu), 8:30–10:00 (JST)
Room9 (Fukuoka International Congress Center 2F 203+204)

Summary: The workshop sheds light on the controversy of adjuvant therapy and discuss about selection of right drugs for light populations in HER2-negative erly breast cancer.

Session Information

Chairs:	Yuko Tanabe	(Department of Medical Oncology, Toranomon Hospital)
	Hiroko Masuda	(Showa University school of medicine, Department of breast surgical oncology,)

SY9-1	Immune checkpoint blockable
	Hope Rugo	(University of California San Francisco Comprehensive Cancer Center)
SY9-2	Adjuvant olaparib for patients with germline BRCA1/2 mutated breast cancer
	Hitomi Sakai	(Advanced Cancer Translational Research Institute, Showa University)
SY9-3	The Role of Fluoropyrimidines in HER2-negative Early Breast Cancer
	Satomi Watanabe	(Kishiwada City Hospital, Department of Medical Oncology)
SY9-4	The role of CDK4/6 inhibitors in early breast cancer
	Yuko Tanabe	(Department of Medical Oncology, Toranomon Hospital)

Symposium 10
Secondary cancers in cancer survivors: challenges and how to face late complications

March 16 (Thu), 8:30–10:00 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Masato Komoda	(Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center)
	SasakiJiichiro	(Division of Clinical Omcology, Department of Comprehensive Medicine, Research and Development Center fo New Medical Frontiers, Kitasato University School of Medicine)

SY10-1	Cancer survivorship research in Japan: Current status and challenges
	Yuri Ito	(Department of Medical Statistics, Research & Development Center, Osaka Medical and Pharmaceutical University)
SY10-2	The Importance of Screening for Secondary Cancers: The Pediatric Oncology Perspective
	Yasushi Ishida	(Pediatric Medical Center Ehime Prefectural Central Hospital)
SY10-3	Task-Sharing and Shift Between Oncologists and Primary Care Physicians Supports Survivorship for Cancer Survivors
	Teruhisa Azuma	(Department of General Internal Medicine, Nara Prefecture General Medical Center)
SY10-4	Secondary cancers in cancer survivors: challenges and how to face late complications
	Naoto Ueno	(The University of Hawai’i Cancer Center (UHCC))

Symposium 11
Shall we discuss the future perspective of combined immunotherapy multidirectionally?

March 16 (Thu), 15:40–17:10 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Masato Takahashi	(Department of Breast Surgery, Hokkaido University Hospital)
	Terufumi Kato	(Department of Thoracic Oncology, Kanagawa Cancer Center)

Discussant:
SY11-KL	Future Prospects of Combined Immunotherapy -The role of Multidisciplinary Team in the Management of Combined Immunotherapy -
	Masahiro Seike	(Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School)
	Akihiko Shimomura	(Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
	Haruna Minami	(Department of Pharmacy, Kyushu University Hospital)
	Yumi Takahashi	(National Hospital Organization Hokkaido Cancer Center nursinng depertment)
	Hatoe Sakamoto	(National Cancer Center Hospital East)

Symposium 12
PD-L1 testing and biomarkers for immune checkpoint blockade.

English Session

March 17 (Fri), 17:20–18:50 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Session Information

Chairs:	Yasushi Yatabe	(Dept. of Diagnostic Pathology National Cancer Center)
	Satoshi Fujii	(Department of Molecular Pathology, Yokohama City University Graduate School of Medicine.)

SY12-1	Assessment on clinical validity of PD-L1 assays in lung cancer
	Yasushi Yatabe	(Dept. of Diagnostic Pathology National Cancer Center)
SY12-2	PD-L1 testing in breast cancer
	Rie Horii	(Department of Pathology, Saitama Cancer Center)
SY12-3	PD-L1 test for head and neck cancer and esophageal cancer
	Satoshi Fujii	(Department of Molecular Pathology, Yokohama City University Graduate School of Medicine.)
SY12-4	PD-L1 Testing in Gastric Cancer
	Tetsuo Ushiku	(Department of Pathology, The University of Tokyo)

Symposium 13
First-line therapy for advanced renal cell cancer

English Session

March 17 (Fri), 8:20–9:50 (JST)
Room3 (MARINE MESSE FUKUOKA Hall A 2F Large Meeting Room)

Summary: There was no single session on metastatic renal cancer treatment at the JSMO GU Educational Symposium in 2021 and 2022.
New combinations have emerged during the recent couple of years, and various clinical trials are now on-going.
Thus, 2023 would be an appropriate time to hold an Educational Symposium focusing on first-line treatment for renal cancer.

Session Information

Chairs:	Yuji MIura	(Department of Medical Oncology, Toranomon Hospital)
	Thomas Powles	(Barts Cancer Institute, Queen Mary University of London)

SY13-1	Strategies for favorable group of metastasis renal cell carcinoma
	Ryosuke Oki	(Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
SY13-2	Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma.
	Junichi Inokuchi	(Department of Urology, Graduate School of Medical Sciences, Kyushu University)
SY13-3	The role of deferred cytoreductive nephrectomy in the era of immune checkpoint inhibitor
	Hiroshi Yaegashi	(Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
SY13-4	Novel combinations in progress in renal cancer
	Thomas Powles	(Barts Cancer Institute, Queen Mary University of London)

Symposium 14
New developments in systemic therapy for pancreatic cancer

English Session

March 17 (Fri), 17:20–18:50 (JST)
Room3 (MARINE MESSE FUKUOKA Hall A 2F Large Meeting Room)

Summary: Chemotherapy of pancreatic cancer will be reviewed by each oncologist on each topic.
Future directions will be discussed comprehensively with overseas oncologists.

Session Information

Chairs:	Masafumi Ikeda	(Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)
	Makoto Ueno	(Department of Gastroenterology, Kanagawa Cancer Center)

SY14-1	Current status of pancreatic cancer treatment in Europe
	Macarulla Teresa	(University of Barcelona)
SY14-2	Current status of first-line treatment of metastatic pancreatic cancer
	Masato Ozaka	(Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
SY14-3	Landscape and future perspectives of second-line chemotherapy for metastatic pancreatic cancer
	Hiroshi Imaoka	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)
SY14-4	Recent treatment strategy for locally advanced pancreatic cancer
	Masashi Kanai	(Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University)
SY14-5	Current status and future perspectives of genetic testing and therapy for hereditary tumors in pancreatic cancer
	Yasuyuki Kawamoto	(Division of Cancer Center, Hokkaido University Hospital)

Symposium 15
Advances in the treatments of rare cancers

English Session

March 17 (Fri), 17:20–18:50 (JST)
Room5 (MARINE MESSE FUKUOKA Hall B 2F Meeting Room 1)

Summary: An increasing number of international clinical trials has been conducted to establish novel treatments for rare cancers in the past decades. This session focuses on globalization of research and development of treatment for rare cancers.

Session Information

Chairs:	Akira Kawai	(Department of Musculoskeletal Oncology, National Cancer Center Hospital)
	Blay Jean-Yves	(Président UNICANCER Directeur Général-General director Centre Léon Bérard)

SY15-1	Reference centers and precision medicine trials in sarcoma
	Blay Jean-Yves	(Président UNICANCER Directeur Général-General director Centre Léon Bérard)
SY15-2	Current Status and Challenges of Treatment for Retroperitoneal Sarcoma in Japan
	Kazunori Honda	(Department of Clinical Oncology Aichi Cancer Center)
SY15-3	Analysis of big data on rare cancers based on National Cancer Registry in Japan
	Tomoyuki Satake	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East / Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
SY15-4	MASTER KEY Project Japan and MASTER KEY Asia; an Asian platform for rare cancers
	Hitomi Okuma	(Department of International Clinical Development, National Cancer Center Hospital)

Symposium 16
Basic knowledge and recent trends of novel oncology drug developmental therapeutics - “Focused”/“Spotlighted”New Drugs

March 17 (Fri), 17:20–18:50 (JST)
Room6 (MARINE MESSE FUKUOKA Hall B 2F Meeting Room 2)

Session Information

Chairs:	Toshio Shimizu	(Department of Medical Oncology Wakayama Medical University Hospital)
	Yutaka Fujiwara	(Department of Thoracic Oncology, Aichi Cancer Center)

SY16-1	New drug development for rare fraction
	Noboru Yamamoto	(Department of Experimental Therapeutics, National Cancer Center Hospital)
SY16-2	The latest research and clnical development into the Antibody–Drug Conjugate (ADC) and the future challenge
	Takahiro Jikoh	(Daiichi Sankyo, Asset and Portfolio Management)
SY16-3	Advances in Bi-specific T-cell Engager (BiTE) and Clinical Development
	Yasutoshi Kuboki	(Department of Experimental Therapeutic, National Cancer Center Hospital East)
SY16-4	Development of chimeric antigen receptor T-cell in hematological and solid malignancies
	Koji Kato	(Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science)

Symposium 17
Current status of therapeutic development for gastroenteropancreatic neuroendocrine neoplasms

English Session

March 17 (Fri), 8:20–9:50 (JST)
Room8 (Fukuoka International Congress Center 2F 201+202)

Summary: This session will provide the opportunity of exchanging information on the current status of therapeutic development for NET/NEC in Japan and Asia.

Session Information

Chairs:	Masato Ozaka	(The Cancer Institute Hospital Of JFCR Hepato-Biliary-Pancreatic Medicine Department)
	Takamasa Oono	(Fukuoka Quarantine Station)

SY17-1	Evidence and Clinical Practice of Peptide Receptor RadionuclideTherapy for Unresectable Neuroendocrine Tumors
	Noritoshi Kobayashi	(Department of Oncology, Yokohama City University Graduate School of Medicine)
SY17-2	Medical treatment in Pancreatic and Gastrointestinal neuroendocrine neoplasm
	Susumu Hijioka	(National Cancer Center Hospital Department of Hepatobiliary and Pancreatic Oncology)
SY17-3	Current status and future perspectives of treatment for advanced gastroenteropancreatic neuroendocrine neoplasms
	Nao Fujimori	(Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University)
SY17-4	Therapeutic development for gastroenteropancreatic neuroendocrine neoplasms
	Chen Ming-Huang	(Department of Oncology, Taipei Veterans General Hospital)

Symposium 18
How to manage the 1st line chemotherapy for esophageal cancer?

English Session

March 17 (Fri), 17:10–18:40 (JST)
Room8 (Fukuoka International Congress Center 2F 201+202)

Summary: According to the results of the CM-648 and KN-590 trials, chemotherapy plus immune checkpoint inhibitor, or nivolumab plus ipilimumab recognized as the standard of care for the first-line chemotherapy for esophageal squamous cell carcinoma. However, there are still many clinical questions, such as how to choose the right combination and how to manage side effects.
Postoperative nivolumab is also being used for clinical practice, and there is room to consider optimal chemotherapy at the time of relapse.
We would like to discuss current issues in perioperative treatment as several strategies are being considered.

Session Information

Chairs:	Ken Kato	(National Cancer Center Hospital)
	Chau Ian	(Royal Marsden Hospital)

Discussant:
SY18-KL	Incorporation of checkpoint inhibitors into first line therapy for oesophageal cancer
	Chau Ian	(Royal Marsden Hospital)
	Hisato Kawakami	(Department of Medical Oncology, Kindai University Faculty of Medicine)
	Takahiro Tsushima	(Division of gastrointestinal oncology, Shizuoka Cancer Center)
	Chih-Hung Hsu	(Department of Oncology, National Taiwan University Hospital /Graduate Institute of Oncology, National Taiwan University College of Medicine)
	Takashi Ogata	(Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan)

Symposium 19
Optimal Treatment Strategy for Head and Neck Cancer in the Era of Immunotherapy – Current Evidence and Future Directions –

English Session

March 17 (Fri), 17:20–18:50 (JST)
Room10 (Fukuoka International Congress Center 4F 409+410)

Summary: The development of the immunotherapy in head and neck cancer (HNC) is pushed forward in not only the field of recurrent or metastatic HNC (RM HNC) but also locally advanced HNC (LA-HNC). The efficacy of the anti-PD-1 antibody and its combination with chemotherapy have been shown in randomized clinical trials for RM-HNC. As a consequence, multiple clinical trials for the novel combination of immune checkpoint inhibitors are undergoing. Furthermore, clinical trials incorporating immune checkpoint inhibitor in surgery and chemoradiotherapy for LA-HNC are pushed forward. However, the interpretation of these clinical trial results and the future development strategies further become complicated.
Based on the foregoing, we have invited two distinguished experts from abroad and asked them to give lectures about these issues.
In the subsequent panel discussion, we are going to discuss the problems and the prospects in the treatment development of HNC with Japanese key opinion leaders (KOLs) of each expertise (head and neck surgery, radiation oncology and medical oncology) and the two overseas experts.

Session Information

Chairs:	Naomi Kiyota	(Kobe University Hospital Cancer Center)
	Makoto Tahara	(Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

Discussant:
SY19-1	How to integrate immunotherapy into treatment strategy for locally advanced head and neck cancer
	Cohen Ezra	(University of California San Diego)
SY19-2	Current Progress in Treatment Strategy for Recurrent or Metastatic Head and Neck Cancer
	Lisa Licitra	(Fondanzione IRCCS Istituto Nazionale dei Tumori, Milan)
	Yuji Murakami	(Department of radiation oncology, Hiroshima university hospital)
	Nobuhiro Hanai	(Department of Head and Neck Surgery, Aichi Cancer Center Hospital)
	Yoshitaka Honma	(Department of Head and Neck, Esophageal Medical Oncology/National Cancer Center Hospital)
	Tomoya Yokota	(Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
	Tomohiro Enokida	(Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

Symposium 20
Evidence and Practice of Advance Care Planning

March 17 (Fri), 8:30–10:00 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Satofumi Shimoyama	(Aichi Cancer Center Hospital)
	Akihiko Shimomura	(Department of Breast and Medical Oncology, National Center for Global Health and Medicine)

SY20-1	How do we integrate advance care planning into cancer treatment?
	Yasuo Hirono	(Cancer Care Promotion Center, University of Fukui Hospital / Department of Gastroenterological surgery, University of Fukui Hospital / Palliative Care Team, University of Fukui Hospital / Chemotherapy Center, University of Fukui Hospital)
SY20-2	What an Oncologist thinks about being a home physician. Tips on ACP from the home physicians
	Shuji Hiramoto	(Department of Clinical Oncology and Palliative care. Peace Home Care Clinic)
SY20-3	Advance care planning -what for and how to put it into practice
	Yoshiyuki Kizawa	(Department of Palliative and Supportive Care, Faculty of Medicine, University of Tsukuba)
SY20-4	ACP and Ethics ~ For Whom and For What? ~
	Michio Miyasaka	(School of Health Sciences, Niigata University)

Symposium 21
How to support elderly cancer patients through multidisciplinary collaboration

March 17 (Fri), 17:20–18:50 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Yukari Tsubata	(Shimane University Hospital)
	Shuko Sakamoto	(Aomori Prefectural Central Hospital)

SY21-1	Current Status and Challenges in the care of older adults with cancer- oncologic decision-making
	Tomohiro Nishijima	(Geriatric Oncology Service, NHO Kyushu Cancer Center)
SY21-2	Support for Elderly Cancer Patients Receiving Outpatient Chemotherapy: A Nurse's Perspective
	Shuko Tamaki	(Nursing department, International Medical Center, Saitama Medical University)
SY21-3	Current Situation and Challenges for Elderly Patients with Cancer: A Pharmacist's Perspective
	Yukiyoshi Fujita	(Division of Pharmacy, Gunma Prefectural Cancer Center)
SY21-4	How to support older patients with cancer by multidisciplinary team.Approach from registered dietitians
	Chie Haneda	(Tokyo Metropolitan Geriatric Medical Center)
SY21-5	Community networks to help patients live the life they want.
	Yumiko Hayasaka	(Kitasato University Hospital Total Support Cener)
SY21-6	Support for Elderly Cancer Patients Receiving Outpatient Chemotherapy: A Care manager's Perspective
	Kazushige Konda	(Kabushikigaisya Cares HakujujiHoumonkangoStation)

Symposium 22
New molecular target therapies based on genome sequencing

English Session

March 17 (Fri), 17:20–18:50 (JST)
Room13 (Fukuoka International Congress Center 5F 502+503)

Summary: Incorporating genome sequencing into hematologic malignancies impacts clinical clinical practice. In this session, we will discuss clinical issues and future challenges, and new target therapies based on genome sequencing in acute leukemia and lymphoma.

Session Information

Chairs:	Yosuke Minami	(Department of Hematology, National Cancer Center Hospital East)
	Katsuto Takenaka	(Department of Hematology, Clinical Immunology and Infectious Diseases Ehime University Graduate School of Medicine)

SY22-1	Identifying novel targets for AML therapy using functional genomic tools
	Takahiro Maeda	(Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences)
SY22-2	Menin inhibitors: A new targeted therapy for patients with AML
	Naval G Daver	(MD Anderson Cancer Center)
SY22-3	Current Status and Prospects of Novel Molecular Targeted Therapy in AML
	Naoko Hosono	(Department of Hematology and Oncology, University of Fukui Hospital)
SY22-4	Genomic Medicine in Malignant Lymphomas
	Daisuke Ennishi	(Center for Comprehensive Genomic Medicine, Okayama University Hospital)
SY22-5	Toward precision medicine in lymphoma: challenges and opportunities
	Hirotaka Nakamura	(National Cancer Center East)

Symposium 23
Future perspective of antibody-drug conjugate (ADC) for various cancer

English Session

March 18 (Sat), 8:30–10:00 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Summary: Antibody-drug conjugates (ADCs) is now being developed for various types of cancer. These drugs are shown to be effective for the disease that is resistant to standard treatment, which is expected to be a significant role in molecular targeted therapies. Given that the targeted molecules are shared between various cancer, understanding of functional mechanisms of ADC across organs is needed. Basic science and the future perspective of each drug will be reviewed and discussed in this session.

Session Information

Chairs:	Yasuhiko Nishioka	(Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences, Tokushima University)
	Eiji Iwama	(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

SY23-1	Antibody-Drug Conjugates (ADCs) in Treatment-Resistant Cancers: From Basic to Clinical Applications
	Kimio Yonesaka	(Department of Medical Oncology, Kindai University Faculty of Medicine)
SY23-2	Future perspective of antibody-drug conjugate (ADC) in oncology
	Aditya Bardia	(Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School)
SY23-3	Enfotulumab vedotin treatment, a novel ADC for urothelial carcinoma
	Motohide Uemura	(Iwase General Hospital, Department of Urology)
SY23-4	Basics in antibody-drug conjugates
	Shino Manabe	(Hoshi University Tohoku University)

Symposium 24
Hope and future: perspectives on complex innovative design

English Session

March 18 (Sat), 10:10–11:40 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Summary: The rising cost in drug development has led to global movements in promoting the efficiency and modernization of clinical trials. Especially in the United States (US), platform trials evaluating several investigational regimens in one trial have been conducted not only for cancer, but also for dementia, Ebola virus, and coronavirus disease 2019. In addition, commercial usage of external data sources (such as an integrated database of electronical medical records) in clinical trials has been actively incorporated in clinical trial designs. These novel ideas are recently termed as complex innovative designs (CIDs), and several pharmaceutical industries and regulatory agencies, such as the US Food and Drug Administration, have staff who are experienced and knowledgeable on the application of CIDs for regulatory purposes. Unfortunately, such activities are seldomly reported in Japan. In this session, two invited speakers will share their experiences on implementing CIDs in the US, and the speakers and invited discussants in Japan will discuss the future directions of cancer clinical trials in Japan.

Session Information

Chairs:	Yasuhiro Fujiwara	(Pharmaceuticals and Medical Devices Agency (PMDA))
	Shogo Nomura	(Graduate School of Medicine, The University of Tokyo)

Discussant:
S24-1	The Future of Platform Trials
	Lori E. Dodd	(Clinical Trials Research Section, Biostatistics Research Branch, NIAID)
S24-2	Accelerating Drug Development with Historic Clinical Trial External Control Arms
	Elizabeth Lamont	(Medidata AI, Medidata, a Dassault Systemes company)
	Kazuki Nozawa	(Department of Breast Oncology, Genome Medical Center, Aichi Cancer Center Hospital)
	Naoki Isogawa	(UCB Japan Co., Ltd.)

Symposium 25
Tumor-agnostic clinical questions in the recent medical oncology field

March 18 (Sat), 14:00–15:30 (JST)
Room2 (MARINE MESSE FUKUOKA Hall A 3F Sub-arena)

Session Information

Chairs:	Hironobu Minami	(Medical Oncology &Hematology, Kobe University Graduate School of Medicine)
	Yu Sunakawa	(Department of Clinical Oncology, St. Marianna University School of Medicine)

SY25-1	Is Comprehensive Genomic Profiling Useful for Cancer Patients? (Pros)
	Sadakatsu Ikeda	(Center for Innovative Cancer Treatment, Tokyo Medical and Dental University Hospital)
SY25-2	Current status of Tissue Agnostic Drug Development in Oncology
	Jun Sato	(Department of Experimental Therapeutics National Cancer Center Hospital)
SY25-3	Is Comprehensive Genomic Profiling Useful for Cancer Patients? (Cons)
	Yasuhito Fujisaka	(Osaka Medical and Pharmaceutical University Hospital Respiratory Medicine and Thoracic Oncology)
SY25-4	IT’s not a “YES or NO” question, but rather a “Success or Fail” question; Tumor agnostic approach for drug development
	Koji Matsumoto	(Hyogo Cancer Center, Division of Medical Oncology)

Symposium 26
Immune and cell therapy for hematologic malignancies

English Session

March 18 (Sat), 10:10–11:40 (JST)
Room6 (MARINE MESSE FUKUOKA Hall B 2F Meeting Room 2)

Summary: Chimeric antigen receptor (CAR) T-cell and bi-specific antibody therapies are an effective new treatment for hematologic malignancies. In this symposium, we will discuss their clinical issues and application in clinical practice.

Session Information

Chairs:	Eisei Kondo	(Dept. of Hematology, Kawasaki Medical School)
	Won Seog Kim	(Samsung Medical Center)

SY26-1	CAR-T for lymphoma
	Stephan Mielke	(Karolinska Institute)
SY26-2	New targets for CAR-T cell therapy against multiple myeloma
	Naoki Hosen	(Dept. of Hematology and Oncology, Osaka University Graduate School of Medicine)
SY26-3	Bi-specific antibody in hematologic malignancies
	Hutchings Martin	(Rigshospitalet, Department of Haematology and Phase 1 Unit)
SY26-4	CD 47: A novel macrophage check point
	Advani Ranjana	(Stanford University)

Symposium 27
Perioperative treatment reloaded: role of immune checkpoint inhibitors and targeted therapies

English Session

March 18 (Sat), 15:00–16:30 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Summary: In 2022, it is expected that postoperative atezolizumab based on the IMpower010 and postoperative osimertinib based on the ADAURA will become available under the National Health Insurance system for patients with resectable non-small cell lung cancer. The development of perioperative treatments, which has been pioneered in breast cancer and other cancers, is now fully launched in non-small cell lung cancer. Many welcome the new options based on the demonstrated benefit in disease free survival (DFS). However, there is some debate about the relevance of DFS in trials using immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs). In this session, we will review the perioperative treatment with ICI and TKI, and also discuss the new evaluation methods that are being introduced for perioperative treatment and the endpoints, including the validity of DFS.

Session Information

Chairs:	Enriqueta Felip	(Vall d’Hebron University Hospital)
	Masahiro Tsuboi	(Department of Thoracic Surgery and Oncplogy, National Cancer Center Hospital East)

SY27-1	Perioperative therapy for resectable NSCLC using tyrosine kinase inhibitors
	Peters Solange	(Lausanne University Hospital)
SY27-2	Perioperative therapy for resectable NSCLC using immune checkpoint inhibitors
	Enriqueta Felip	(Vall d’Hebron University Hospital)
SY27-3	Novel methods in evaluation of perioperative treatment for resectable NSCLC
	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital)
SY27-4	Statistical challenges when selecting primary endpoint(s) in perioperative RCTs in NSCLC
	Shogo Nomura	(Graduate school of Medicine, The University of Tokyo)

Symposium 28
Future Prospects for Treatment of Cancer Cachexia

March 18 (Sat), 10:10–11:40 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Mitsue Saito	(Department of Breast Oncology, Juntendo University)
	Atsushi Sato	(Hirosaki University Graduate School of Medicine Department of Medical Oncology)

SY28-1	Historical overview of cancer cachexia management
	Tateaki Naito	(Division of Thoracic Oncology, Shizuoka Cancer Center, Japan)
SY28-2	Nutrition management for cancer cachexia: current status and future prospects
	Junko Ueshima	(Department of Nutritional Service, NTT Medical Center Tokyo)
SY28-3	From the perspective of cancer rehabilitation
	Tetsuya Tsuji	(Department of Rehabilitation Medicine, Keio University School of medicine)
SY28-4	The usefulness of "Team Anamorelin" a multidisciplinary care team for cancer cachexia
	Shinji Kimoto	(Department of Pharmacy, Takeda General Hospital)
SY28-5	Development of holistic multimodal care for cancer cachexia
	Koji Amano	(Department of palliative medicine, National Cancer Center Hospital)
SY28-6	Comprehensive treatment of cancer-associated cachexia
	Koichi Takayama	(Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.)

Symposium 29
Essence of Guidelines for Psychiatric Symptoms in Cancer Care

March 18 (Sat), 14:00–15:30 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Masaya Shimamoto	(National Hospital Organization Kyushu Cancer Center Department of Palliative and Supportive Care)
	Hiromichi Matsuoka	(Department of Psycho-Oncology, National Cancer Center Hospital)

SY29-1	Practice Guidelines for Psychological Distress in Patients with Cancer (preliminary report)
	Daisuke Fujisawa	(Keio University / National Cancer Center)
SY29-2	Psychiatric symptoms in bereaved families:Considerations for healthcare professionals involved in cancer care.
	Noriko Setou	(Department of Disaster Psychiatry, Fukushima Medical University)
SY29-3	Patient-healthcare provider communication in cancer care: JPOS-JASCC Clinical Practice Guidelines
	Nobuya Akizuki	(Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Department of Psyco-Oncology)
SY29-4	Revision of JPOS/ JASCC clinical guidelines for delirium in adult cancer patients: The essence of recommendation statements
	Takatoshi Hirayama	(Department of Psycho-Oncology, National Cancer Center Hospital, Japan)

ASCO/JSMO Joint Symposium

ASCO/JSMO Joint Symposium
Emerging novel therapy (including new generation CAR-T, BiTE, cancer RNA vaccine)

English Session

March 16 (Thu), 10:10–11:40 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Session Information

Chairs:	Lynn Schuchter	(ASCO President / Clinical Oncology, Madlyn & Leonard Abramson / Tara Millar Melanoma Center)
	Chikashi Ishioka	(Department of Clinical Oncology, Tohoku University Graduate School of Medicine / Department of Medical Oncology, Tohoku University Hospital)

AJS-1	Navigating the expanding treatment landscape in R/R diffuse large B-cell lymphoma, how to incorporate CAR T-celltherapy and bispecific antibodies
	Loretta J. Nastoupil	(Department of Lymphoma / Myeloma, UT MD Anderson Cancer Center)
AJS-2	Bispecific and CAR T-cell immunotherapies for Advanced Prostate Cancer
	Jessica E. Hawley	(Division of Medical Oncology, University of Washington / Clinical Research Division, Fred Hutch Cancer Center)
AJS-3	Current status and challenges of development of ground-breaking cancer therapy in Japan
	Yasutoshi Kuboki	(National Cancer Center Hospital East Department of Experimental Therapeutics)
AJS-4	Current Status and Future Challenges in Clinical Development of CAR-T Cell Therapy and Bispecific Antibody Therapy for Solid Tumors
	Shigehisa Kitano	(Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)

ESMO/JSMO Joint Symposium

ESMO/JSMO Joint Symposium
Cutting-edge precision oncology (including ctDNA/RNA, WGS/WES, multi-omics analyses)

English Session

March 17 (Fri), 17:20–18:50 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Session Information

Chairs:	Andrés Cervantes	(Biomedical Research Inst. INCLIVA University of Valencia)
	Takayuki Yoshino	(National Cancer Cemter Hospital East)

EJS-1	ctDNA testing in the management of colorectal cancer patients
	Nicola Normanno	(Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy)
EJS-2	Focusing on precision medicine in lung cancer
	Solange Peters	(Lausanne University Hospital, CHUV, Lausanne, Switzerland)
EJS-3	Multi-omics-based Precision Oncology for Patients with Advanced Solid Tumors
	Yoshiaki Nakamura	(National Cancer Center Hospital East)
EJS-4	Development of molecularly-stratified precision medicine in lung cancer
	Shingo Matsumoto	(Department of Thoracic Oncology, National Cancer Center Hospital East)

Asia-Pacific/JSMO Joint Symposium

Asia-Pacific/JSMO Joint Symposium
Digital transformation in clinical practice and trials (including telemedicine, eConsent/ePRO)

English Session

March 18 (Sat), 8:30–10:00 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Session Information

Chairs:	Takako Nakajima	(Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
	Sung-Bae Kim	(Asan Medical Center)

APJS-1	Patient First - Digital Clinical Trials and Decentralized Clinical Trials - We are at an Inflection Point?
	Rakesh Maniar	(MSD, TransCelerate)
APJS-2	The latest global trends of Decentralized Clinical Trial (DCT) and the role of academia for domestic implementation in Japan
	Shinya Yamamoto	(Link & Innovation, Inc. / SCIENCE 37, INC. / Deep Intelligent Pharma Co., Ltd. / Oncoshot Pte Ltd / Clinical Research, Innovation and Education Center, Tohoku University Hospital (CRIETO) / Professional University of Information and Management for Innovation / Hosei Business School of Innovation Management)
APJS-3	The Challenges and Case Studies of Digital Transformation: A perspective of Health Tech Vendor.
	Mohammad Imran, Kenta Kachi	(3H Clinical Trial Inc. / 3H Medi Solution Inc)
APJS-4	Digitization in Oncology in Japan: from Hospital
	Yasushi Goto	(National Cancer Center Hospital Department of Thoracic Oncology)

DIA/JSMO Joint Symposium

DIA/JSMO Joint Symposium
Novel International Clinical Research Design and its Regulation

English Session

March 17 (Fri), 8:20–9:50 (JST)
Room9 (Fukuoka International Congress Center 2F 203+204)

Session Information

Chairs:	Yoshiaki Uyama	(Pharmaceuticals and Medical Devices Agency)
	Akihiro Sato	(National Cancer Center Hospital East)

DJS-1	Regulatory challenges in the Asian clinical TriaLs network for cAancerS (ATLAS) project
	Kenichi Nakamura	(Department of International Clinical Development, National Cancer Center Hospital)
DJS-2	Our commitment to better patient outcome by bridging evidence gaps
	Matthew Robson	(Novartis Pharma K.K.)
DJS-3	The paradigm of drug development with innovation from APAC
	Hsu Vicky	(Greater China Region Head and Head of Biotech Operations APAC , Parexel International)
DJS-4	Utilization of clinical research data other than conventional clinical trials for pharmaceuticals and medical devices
	Haruko Yamamoto	(Pharmaceuticals and Medical Devices Agency)

SIOG/JSMO Joint Symposium

SIOG/JSMO Joint Symposium
Current and Future of Financial Toxicity

English Session

March 18 (Sat), 10:10–11:40 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Session Information

Chairs:	Tomonori Mizutani	(Department of Medical Oncology, Kyorin University Faculty of Medicine)
	Hiroshi Yamamoto	(Tokyo Metropolitan Geriatric Hospital)

SJS-1	An Overview of Geriatric Oncology in Global Clinical Practice: a SIOG National Representatives’ Survey
	Tomonori Mizutani	(Department of Medical Oncology, Kyorin University Faculty of Medicine)
SJS-2	Geriatric Oncology in the US: Updates on Interventions, Infrastructure, and Guidelines
	Dale William	(City of Hope)
SJS-3	Geriatric Oncology in Australia
	Heather Patricia Lane	(Geriatric Acute and Rehabilitation Medicine, Sir Charles Gairdner Hospital)
SJS-4	The Current Landscape of Geriatric Oncology in Japan
	Ayumu Matsuoka	(Division of Supportive Care, Survivorship and Translational Research, Institute for Cancer Control, National Cancer Center)

Joint Symposium

Joint Symposium 1
Cancer Genomic Medicine and Beyond

English Session

March 16 (Thu), 15:40–17:10 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Session Information

Chairs:	Hiroyuki Mano	(National Cancer Center)
	Seiji Yano	(Department of Respiratory Medicine, Faculty of Medicine, Kanazawa University)

JS1-1	Aggregating comprehensive cancer genomic data and clinical information into C-CAT for utilization
	Yusuke Okuma	(Section of Liaison for Cancer Genomic Medicine Hospitals, Center for Cancer Genomic and Advanced Therapeutics, National Cancer Center)
JS1-2	Toward efficient operation of expert panels
	Keigo Komine	(Department of Medical Oncology, Tohoku University Hospital)
JS1-3	Optimizing Cancer Genome Medicine in Clinical Practice in Japan
	Manabu Muto	(Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine)
JS1-4	Liquid Biopsy-guided Precision Oncology in Advanced Solid Tumors
	Yoshiaki Nakamura	(National Cancer Center Hospital East)
JS1-5	Whole genome sequencing-based precision cancer medicine in Japan
	TakashiKohno	(Div Genome Biol, Natl Cancer Ctr Res Inst)
JS1-6	Imagine all the patients living life without recurrence
	Eiji Oki	(Department Surgery and Scinece, Graduate School of Medical Sciences, Kyushu University)

Joint Symposium 2
Symptom Management of Bone Metastases

March 16 (Thu), 10:10–11:40 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Toshimi Takano	(Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR)
	Eriko Satomi	(Department of Palliative medicine, National Cancer Center Hospital)

JS2-1	Necessity of comprehensive approach for bone metastases by multimodal team - from the 2nd edition of JSMO guideline -
	Hiroyuki Shibata	(Department of Clinical Oncology, Graduate School of Medicine, Akita University)
JS2-2	Comprehensive management for skeletal metastasis in cancer patients
	Tatsuya Takagi	(Juntendo University Department of Orthopedic Surgery, Rehabilitation Medicine, Palliative Care Center)
JS2-3	Palliative radiotherapy for bone metastases in the multidisciplinary treatment
	Naoki Nakamura	(Department of Radiation Oncology, St. Marianna University School of Medicine)
JS2-4	Pain Management in Bone Metastasis
	Yoshihisa Matsumoto	(Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
JS2-5	The Role of Occupational Therapist in the Rehabilitation of Bone Metastases
	Takuro Sakurai	(Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital)
JS2-6	Medication-Related Osteonecrosis of the Jaw Associated with Long-Term Administration of Bone Modifying Agents ~ Current Consensus on Oral Management to Support Cancer Patients' Treatment and Lives ~
	Takao Ueno	(National Cancer Center Hosital Dentistry)
JS2-7	Supporting the Life of Patients with Bone Metastases through Bone Meta- Conference - Team Approach at a Regional Core Hospital
	Teruhisa Azuma	(Department of General Internal Medicine, Nara Prefecture General Medical Center)

Joint Symposium 3
New developments in targeted radionuclide therapy

March 17 (Fri), 9:40–11:10 (JST)
Room6 (MARINE MESSE FUKUOKA Hall B 2F Meeting Room 2)

Session Information

Chairs:	Sadamoto Zenda	(National Cancer Center Hospital East)
	Katsumasa Nakamura	(Department of Radiation Oncology, Hamamatsu University School of Medicine)

JS3-1	Evidence of clinical trials for lutetium (¹⁷⁷Lu) oxodotreotide
	Masafumi Ikeda	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)
JS3-2	Peptide Receptor Radionuclide Therapy (PRRT) for Medical Oncologist
	Kazuhiro Yanagihara	(Department of Medical Oncology, Kansai Electric Power Hospital)
JS3-3	Clinical Practice of Peptide Receptor Radionuclide Therapy using ¹⁷⁷Lu-DOTATATE in Japan
	Shoko Takano	(Yokohama city university graduate school of medicine, department of radiation oncology)
JS3-4	Targeted Radioisotope Therapy (TRT): Current Status and Issues
	Koichiro Abe	(Department of Radiology, Tokyo Medical University)

Joint Symposium 4
Anti-cancer medicine and cardiovascular adverse events

March 18 (Sat), 8:30–10:00 (JST)
Room9 (Fukuoka International Congress Center 2F 203+204)

Session Information

Chairs:	Yoshihiro Fukumoto	(Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine)
	Masanobu Takahashi	(Department of Clinical Oncology, Tohoku University Graduate School of Medicine)

JS4-1	Clinical Practice Guidelines in Cardio-Oncology and the Definition of Cancer Therapy-Related Cardiovascular Toxicity
	Kazuhiro Sase	(Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University)
JS4-2	Imaging Evaluation of Chemotherapeutics-related Cardiac Dysfunction in Breast Cancer Patients
	Koichiro Sugimura	(Department of Cardiology, International University of Health and Welfare, Narita Hospital)
JS4-3	Cardiovascular adverse events and prognosis in patients with hematologic malignancies and breast cancer treated with anticancer agents in late 2010s: the Kurume-CREO registry
	Tatsuhiro Shibata	(Department of Internal Medicine, Division of Cardiovascular Medicine, Kurume University Hospital)
JS4-4	What should oncologists know about venous thromboembolism in cancer patients? ~Onco-Cardiology~
	Yugo Yamashita	(Kyoto University Hospital, Department of Cardiovascular Medicine)
JS4-5	Cardiovascular adverse events that oncologists should know
	Toru Mukohara	(Department of Medical Oncology, National Cancer Center Hospital East)
JS4-6	Efficacy and safety of DOAC for treatments of VTE in patients undergoing cancer drug treatment
	Keigo Komine	(Department of Medical Oncology, Tohoku University Hospital)

Joint Symposium 5
Tips for genetic medicine encountered in precision oncology

March 18 (Sat), 10:10–11:40 (JST)
Room9 (Fukuoka International Congress Center 2F 203+204)

Session Information

Chairs:	Issei Imoto	(Aichi Cancer Center Research Institute)
	Katsuya Tsuchihara	(Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)

JS5-1	Cancer precision medicine and genetic disease
	Akira Hirasawa	(Department of Clinical Genetics and Genomic Medicine, Okayama University Hospital)
JS5-2	Management of germline findings(secondary findings) detected by comprehensive genome analysis
	Nobuhiro Kado	(Shizuoka cancer center Division of Genetic medicine promotion (Cancer genetic counseling/Cancer tumor board)Division of Gynecology)
JS5-3	Response to non-cancer germline findings -Approach to the Future-
	Natsuko Inagaki	(Tokyo medical university Department of Cardiology Clinical Genetics Center)
JS5-4	Clinical significance of genetic profiling for cancer patients and their blood-relatives in precision oncology era
	Takeshi Kuwata	(Department of Genetic Medicine and Services National Cancer Center Hospital East)

Joint Symposium 6
Implementing Patients' Voices to the Field: Challenges and Future of Qualitative Research

March 18 (Sat), 8:30–10:00 (JST)
Room12 (Fukuoka International Congress Center 5F 501)

Session Information

Chairs:	Kaori Yagasaki	(Faculty of Nursing and Medical Care, Keio University)
	Shimizu Chikako	(Department of Breast and Medical Oncology, National Center for Global Health and Medicine)

JS6-1	Qualitative Research and Patient-centered Cancer Nursing Practice
	Harue Arao	(Osaka University Graduate School of Medicine)
JS6-2	Putting the voices of patients and frontline workers into practice: Using qualitative methods in implementation science
	Taichi Shimazu	(Division of Behavioral Sciences, Institute for Cancer Control, National Cancer Center)
JS6-3	Development of cancer disease-specific quality of life scales and their implementation in clinical trials
	Yuichiro Kikawa	(Kansai Medical University Hospital, Department of Breast Surgery)
JS6-4	Appearance Care Development Research - Research Strategy for Return to the Field
	Keiko Nozawa	(Department of Nursing, Mejiro University)
JS6-5	Don't say "Thank you for your valuable comment"!
	Naomi Sakurai	(Cancer Survivors Recruiting Project,General Incorporated Association / Cancer Solutions, Co,LTD)

Committee Program

Committee Program 1
JSMO Committee on Public Information and Negotiation Program

March 16 (Thu), 10:10–11:40 (JST)
Room6 (MARINE MESSE FUKUOKA Hall B 2F Meeting Room 2)

Session Information

Chairs:	Manabu Muto	(Kyoto University Graduate School of Medicine, Department of Therapeutic Oncology)
	Minoru Fukuda	(Cancer Treatment Center, Nagasaki Prefecture Shimabara Hospital)

Role of smoking cessation interventions in dentistry
	Koji Inagaki	(Department of Dental Hygiene, Aichi Gakuin University Junior College)
perioperative smoking cessation
	Kumiko Tanabe	(Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine)
Digital Medicine for Smoking Cessation
	Akihiro Nomura	(College of Transdisciplinary Sciences for Innovation, Kanazawa University)

Committee Program 2
Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region

English Session

March 16 (Thu), 8:30–10:00 (JST)
Room7 (Fukuoka International Congress Center 3F Main Hall)

Summary: In recent years, innovative cancer drug therapies have been developed, and cancer treatment is advancing rapidly. Many excellent academic organizations in Asia-Pacific countries aim to promote and further develop such cancer therapies. However, the Asia-Pacific region is very diverse regarding ethnicity, social systems, and health insurance systems, even though the areas are relatively close. This diversity is no exception in the educational systems, academic programs, and educational activities related to medical oncology. In this session, members of the education-related committees of MOGA, CSCO, KSMO, SSO, TOS, and JSMO, which contribute to medical oncology education in the Asia-Pacific region, will present and discuss their efforts and prospects for the education of medical oncology in their respective societies. The symposium aims to promote mutual understanding among the Asia-Pacific region regarding medical oncology education.

Session Information

Chairs:	Ichiro Kinoshita	(Division of Clinical Cancer Genomics, Hokkaido University Hospital)
	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

Oncology Education Initiatives at MOGA
	Deme Karikios	(Medical Oncologist, Nepean Cancer and Wellness Centre, Nepean Hospital / Senior Clinical Lecturer, Sydney Medical School, University of Sydney)
Oncology Education Initiatives at (Chinese Society of Clinical Oncology) CSCO
	Jia Zhong	(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)
Development of Oncology Fellowship between KSMO and KCSG in Korea: Current Status of Oncology Education and Framework for Future Oncology of KSMO
	Yeon Hee Park	(Samsung Medical Center / Sungkyunkwan University School of Medicine)
Oncology Education Initiatives at Singapore Society of Oncology(SSO)
	Eileen Yi Ling Poon	(National Cancer Centre Singapore)
Oncology Education Initiatives at Taiwan Oncology Society (TOS)
	Chiun Hsu	(Department of Medical Oncology, National Taiwan University Cancer Center / Graduate Institute of Oncology, National Taiwan University College of Medicine)
Oncology Education Initiatives at JSMO
	Ichiro Kinoshita	(Division of Clinical Cancer Genomics, Hokkaido University Hospital)

Committee Program 3
Overview of Oncocardiology guideline

March 16 (Thu), 14:55–15:40 (JST)
Room8 (Fukuoka International Congress Center 2F 201+202)

Session Information

Chair:	Shingo Yano	(Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine)

Echocardiography in the era of Oncocardiology
	Hirotsugu Yamada	(Tokushima University Graduate School of Biomedical Sciences, Department of Community Medicine for Cardiology)
Immune checkpoint inhibitors-associated myocarditis
	Masaaki Shoji	(Department of Cardiology, National Cancer Center Hospital)
Venous thromboembolism in the era of Oncocardiology
	Dai Maruyama	(Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)

Committee Program 4
Part1:Overview of JSMO Cancer Immunotherapy Guideline, Third Edition

March 16 (Thu), 15:50–17:20 (JST)
Room8 (Fukuoka International Congress Center 2F 201+202)

Session Information

Chairs:	Katsuyuki Hotta	(Center for Clinical Innovative Medicine, Okayama University Hospital)
	Yutaka Fujiwara	(Department of Thoracic Oncology, Aichi Cancer Center)

Key Points for Revision of the 3rd Edition / Cross-Cancer Type Evaluation and Statement
	Kiichiro Ninomiya	(Center for Comprehensive Genomic Medicine, Okayama University Hospital)
New Cancer Immunotherapy / CAR T-cell therapy and Bispecific antibodies
	Noriko Fukuhara	(Department of Hematology, Tohoku University Hospital)
Evidence for Cancer Vaccine therapy and Immuno-Cell therapy
	Tatsunori Shimoi	(National Cancer Center Hospital)

Committee Program 4
Part2: Molecular Testing for Colorectal Cancer Treatment: Key points of the revision

March 16 (Thu), 15:50–17:20 (JST)
Room8 (Fukuoka International Congress Center 2F 201+202)

Session Information

Chair:	Hiromichi Ebi	(Division of Molecular Therapeutics, Aichi Cancer Center)

Overview
	Hideaki Bando	(Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)
HER2 testing in colorectal cancer
	Kentaro Sawada	(Kushiro Rosai Hospital, Medical Oncology)
Comprehensive genomic profiling test and liquid biopsy for colorectal cancer
	Kyoko Yamaguchi	(Department of Clinical Education Center/Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital)

Educational Lecture

Educational Lecture 1

March 16 (Thu), 8:30–9:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL1	Basics of Tumor Immunology
	Shigehisa Kitano	(Department of Advanced Medical Development)

Educational Lecture 2

March 16 (Thu), 9:00–9:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL2	Basic tumor biology (Cancer Genomics)
	Tatsuhiro Shibata	(Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo / National Cancer Center)

Educational Lecture 3

March 16 (Thu), 9:30–10:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL3	Impact of Gut Microbiome on Cancer Immunity
	Kiyoshi Yoshimura	(Department of Clinical Immuno Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University)

Educational Lecture 4

March 16 (Thu), 10:15–10:45 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL4	Chemotherapy/Chemotherapeutic agents
	Hiroki Ueda	(Naga Municipal Hospital)

Educational Lecture 5

March 16 (Thu), 10:45–11:15 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL5	Targeted Therapy
	Hidetoshi Hayashi	(Department of Medical Oncology, Faculty of Medicine, Kindai University)

Educational Lecture 6

March 16 (Thu), 11:15–11:45 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL6	Supportive Care in Cancer and Adverse Event Management
	Tateaki Naito	(Division of Thoracic Oncology, Shizuoka Cancer Center)

Educational Lecture 7

March 16 (Thu), 14:00–14:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL7	Oncologic emergency and Paraneoplastic syndrome
	Takashi Tanaka	(Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)

Educational Lecture 8

March 16 (Thu), 14:30–15:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL8	Usefulness of geriatric assessment in cancer treatment for older patients
	Yukari Tsubata	(Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine)

Educational Lecture 9

March 16 (Thu), 15:00–15:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL9	Palliative care for total pain
	Tomohiro Nishi	(Department of Medical Oncology, Kawasaki Municipal Ida Hospital)

Educational Lecture 10

March 16 (Thu), 15:40–16:10 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL10	Psyho-Oncology / Advance Care Planning
	Nobuya Akizuki	(Tokyo Metoropolitan Cancer and Infectious Diseases Center Komagome Hospital)

Educational Lecture 11

March 16 (Thu), 16:10–16:40 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL11	The current situation and future direction in the treatment of head and neck cancer and thyroid cancer
	Tomohiro Enokida	(Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Japan.)

Educational Lecture 12

March 16 (Thu), 16:40–17:10 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL12	Esophageal Cancer and Gastric Cancer
	Yasuo Hamamoto	(Keio Cancer Center, Keio University School of Medicine)

Educational Lecture 13

March 17 (Fri), 8:20–8:50 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL13	Colorectal cancer and small bowel cancer
	Atsuo Takashima	(Department of Gastrointestinal Medical Oncology)

Educational Lecture 14

March 17 (Fri), 8:50–9:20 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL14	Importance of systemic chemotherapy in combination with locoregional therapy and in conversion to locoregional therapy for hepatocellular carcinoma
	Kazuomi Ueshima	(Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine)

Educational Lecture 15

March 17 (Fri), 9:20–9:50 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL15	Chemotherapy of Biliary Tract Cancer and Pancreatic Cancer
	Tatsuya Ioka	(Oncology center, Yamaguchi University Hospital)

Educational Lecture 16

March 17 (Fri), 9:50–10:20 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL16	The up to date of chemotherapy for cervical cancer and endometrial cancer
	Tadaaki Nishikawa	(National Cancer Center Hospital Department of Medical Oncology)

Educational Lecture 17

March 17 (Fri), 10:20–10:50 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL17	Standard treatment for ovarian cancer
	Kenichi Harano	(Department of Experimental Therapeutics/ Medical Oncology, National Cancer Center Hospital East)

Educational Lecture 18

March 17 (Fri), 10:50–11:20 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL18	Systemic therapy for genitourinary cancers
	Hiroshi Kitamura	(Department of Urology, Faculty of Medicine, University of Toyama)

Educational Lecture 19

March 17 (Fri), 16:20–16:50 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL19	Conflicts of Interest Management for Clinical Research
	Saburo Sone	(Tokushima University)

Educational Lecture 20

March 17 (Fri), 16:50–17:20 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL20	Small cell lung cancer and malignant mesothelioma
	Kiichiro Ninomiya	(Center for Comprehensive Genomic Medicine, Okayama University Hospital)

Educational Lecture 21

March 17 (Fri), 17:20–17:50 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL21	Overview of the development in the treatment for non-small cell lung cancer in 2022
	Satoru Miura	(Department of Internal Medicine, Niigata Cancer Center Hospital)

Educational Lecture 22

March 17 (Fri), 17:50–18:20 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL22	Breast cancer (Neo/Adjuvant chemotherapy)
	Fumikata Hara	(Cancer Institute Hospital of JFCR Department of Breast Medical Oncology)

Educational Lecture 23

March 17 (Fri), 18:20–18:50 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL23	Breast cancer (management for recurrent breast cancer)
	Yoichi Naito	(Department of General Internal Medicine, National Cancer Center Hospital East)

Educational Lecture 24

March 18 (Sat), 8:30–9:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL24	bone and soft tissue tumors
	Yu Oyama	(Department of Medical Oncology Kameda Medical Center)

Educational Lecture 25

March 18 (Sat), 9:00–9:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL25	Recent Advances in the Treatment of Malignant Lymphoma
	Rika Sakai	(Department of Hematology and Medical Oncology Kanagawa Cancer Center)

Educational Lecture 26

March 18 (Sat), 9:30–10:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL26	Leukemia Treatment by Oncologists in Outpatient Settings
	Kimikazu Yakushijin	(Department of Medical Oncology and Hematology, Kobe University Hospital)

Educational Lecture 27

March 18 (Sat), 10:10–10:40 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL27	2023 treatment algorithm for multiple myeloma- every year a new standard ?
	Yuichiro Nawa	(Division of Hematology, Ehime Prefectural Central Hospital)

Educational Lecture 28

March 18 (Sat), 10:40–11:10 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL28	NEN (neuroendocrine neoplasm), GIST (gastrointestinal stromal tumor)
	Katsunori Shinozaki	(Division of Clinical Oncology Hiroshima Prefectural Hospital)

Educational Lecture 29

March 18 (Sat), 11:10–11:40 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL29	Skin Cancer
	Aya Nishizawa	(Tokyo Metoropolitan Cancer and Infection diseases Center Komagome Hospital)

Educational Lecture 30

March 18 (Sat), 14:00–14:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL30	Therapeutic strategy for primary unknown cancer (CUP)
	Junko Tanizaki	(Department of Medical Oncology, Kindai University Faculty of Medicine)

Educational Lecture 31

March 18 (Sat), 14:30–15:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL31	Pediatric Cancer
	Motohiro Kato	(Department of Pediatrics, the University of Tokyo)

Educational Lecture 32

March 18 (Sat), 15:00–15:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL32	Current Status of Precision Oncology in Japan
	Kuniko Sunami	(Department of Laboratory Medicine, National Cancer Center Hospital)

Educational Lecture 33

March 18 (Sat), 15:30–16:00 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL33	Primary brain tumor, metastatic brain tumor
	Yukihiko Sonoda	(Department of Neurosurgery, Faculty of Medicine Yamagata University)

Educational Lecture 34

March 18 (Sat), 16:00–16:30 (JST)
Room4 (MARINE MESSE FUKUOKA Hall B 1F Exhibition Room)

Session Information

EL34	Clinical trials act / Personal Data Protection
	Katsuyuki Hotta	(Center for Clinical Innovative Medicine, Okayama University Hospital)

Program

Dates

Special Lecture

Anniversary Lecture

Presidential Session

Presidential Session 1 (Lung cancer/Thoracic Cancer)

Presidential Session 2 (Breast Cancer)

Presidential Session 3 (Miscellaneous)

Presidential Session 4 (Gastrointestinal Cancer)

Highlight of the Day

Highlight of the Day 1

Highlight of the Day 2

Highlight of the Day 3

Presidential Symposium

Presidential Symposium 1Current and Future of Financial Toxicity

Presidential Symposium 2The Present and Future of Drug Development for Asian Rare Cancers in the World

Presidential Symposium 3Future perspectives of emerging therapies for gastroesophageal adenocarcinoma

Presidential Symposium 4

Presidential Symposium 5Career empowerment plans in JSMO

Symposium

Symposium 1Future perspectives of molecular targets for GI cancer

Symposium 2Part1:Overview of JSMO Cancer Immunotherapy Guideline, Third EditionEvolution of investigator-initiated registration-directed trials under J-GCP

Symposium 3Next cancer immunotherapy

Symposium 4Future direction of digital health apps and SaMD (software as medical device)

Symposium 5Treatment for advanced or recurrent cervical cancer: up to date and controversial

Symposium 6Considering optimal treatment of premenopausal breast cancer

Symposium 7Update to Strategies for the Treatment of NSCLC with Driver Gene Mutation

Symposium 8Reviewing the role of proper use of genetic alteration specific/tumor - agnostic driven anti-cancer drugs and cancer genomic panel testings

Symposium 9Individualizing Adjuvant Therapy in patients with HER2-negative breast cancer

Symposium 10Secondary cancers in cancer survivors: challenges and how to face late complications

Symposium 11Shall we discuss the future perspective of combined immunotherapy multidirectionally?

Symposium 12PD-L1 testing and biomarkers for immune checkpoint blockade.

Symposium 13First-line therapy for advanced renal cell cancer

Symposium 14New developments in systemic therapy for pancreatic cancer

Symposium 15Advances in the treatments of rare cancers

Symposium 16Basic knowledge and recent trends of novel oncology drug developmental therapeutics - “Focused”/“Spotlighted”New Drugs

Symposium 17Current status of therapeutic development for gastroenteropancreatic neuroendocrine neoplasms

Symposium 18How to manage the 1st line chemotherapy for esophageal cancer?

Symposium 19Optimal Treatment Strategy for Head and Neck Cancer in the Era of Immunotherapy – Current Evidence and Future Directions –

Symposium 20Evidence and Practice of Advance Care Planning

Symposium 21How to support elderly cancer patients through multidisciplinary collaboration

Symposium 22New molecular target therapies based on genome sequencing

Symposium 23Future perspective of antibody-drug conjugate (ADC) for various cancer

Symposium 24Hope and future: perspectives on complex innovative design

Symposium 25Tumor-agnostic clinical questions in the recent medical oncology field

Symposium 26Immune and cell therapy for hematologic malignancies

Symposium 27Perioperative treatment reloaded: role of immune checkpoint inhibitors and targeted therapies

Symposium 28Future Prospects for Treatment of Cancer Cachexia

Symposium 29Essence of Guidelines for Psychiatric Symptoms in Cancer Care

ASCO/JSMO Joint Symposium

ASCO/JSMO Joint SymposiumEmerging novel therapy (including new generation CAR-T, BiTE, cancer RNA vaccine)

ESMO/JSMO Joint Symposium

ESMO/JSMO Joint SymposiumCutting-edge precision oncology (including ctDNA/RNA, WGS/WES, multi-omics analyses)

Asia-Pacific/JSMO Joint Symposium

Asia-Pacific/JSMO Joint SymposiumDigital transformation in clinical practice and trials (including telemedicine, eConsent/ePRO)

DIA/JSMO Joint Symposium

DIA/JSMO Joint SymposiumNovel International Clinical Research Design and its Regulation

SIOG/JSMO Joint Symposium

SIOG/JSMO Joint SymposiumCurrent and Future of Financial Toxicity

Joint Symposium

Joint Symposium 1Cancer Genomic Medicine and Beyond

Joint Symposium 2 Symptom Management of Bone Metastases

Joint Symposium 3New developments in targeted radionuclide therapy

Joint Symposium 4Anti-cancer medicine and cardiovascular adverse events

Joint Symposium 5Tips for genetic medicine encountered in precision oncology

Joint Symposium 6Implementing Patients' Voices to the Field: Challenges and Future of Qualitative Research

Committee Program

Committee Program 1JSMO Committee on Public Information and Negotiation Program

Committee Program 2Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region

Committee Program 3Overview of Oncocardiology guideline

Committee Program 4Part1:Overview of JSMO Cancer Immunotherapy Guideline, Third Edition

Committee Program 4Part2: Molecular Testing for Colorectal Cancer Treatment: Key points of the revision

Educational Lecture

Educational Lecture 1

Educational Lecture 2

Educational Lecture 3

Educational Lecture 4

Educational Lecture 5

Educational Lecture 6

Educational Lecture 7

Presidential Symposium 1
Current and Future of Financial Toxicity

Presidential Symposium 2
The Present and Future of Drug Development for Asian Rare Cancers in the World

Presidential Symposium 3
Future perspectives of emerging therapies for gastroesophageal adenocarcinoma

Presidential Symposium 5
Career empowerment plans in JSMO

Symposium 1
Future perspectives of molecular targets for GI cancer

Symposium 2
Part1:Overview of JSMO Cancer Immunotherapy Guideline, Third Edition
Evolution of investigator-initiated registration-directed trials under J-GCP

Symposium 3
Next cancer immunotherapy

Symposium 4
Future direction of digital health apps and SaMD (software as medical device)

Symposium 5
Treatment for advanced or recurrent cervical cancer: up to date and controversial

Symposium 6
Considering optimal treatment of premenopausal breast cancer

Symposium 7
Update to Strategies for the Treatment of NSCLC with Driver Gene Mutation

Symposium 8
Reviewing the role of proper use of genetic alteration specific/tumor - agnostic driven anti-cancer drugs and cancer genomic panel testings

Symposium 9
Individualizing Adjuvant Therapy in patients with HER2-negative breast cancer

Symposium 10
Secondary cancers in cancer survivors: challenges and how to face late complications

Symposium 11
Shall we discuss the future perspective of combined immunotherapy multidirectionally?

Symposium 12
PD-L1 testing and biomarkers for immune checkpoint blockade.

Symposium 13
First-line therapy for advanced renal cell cancer

Symposium 14
New developments in systemic therapy for pancreatic cancer

Symposium 15
Advances in the treatments of rare cancers

Symposium 16
Basic knowledge and recent trends of novel oncology drug developmental therapeutics - “Focused”/“Spotlighted”New Drugs

Symposium 17
Current status of therapeutic development for gastroenteropancreatic neuroendocrine neoplasms

Symposium 18
How to manage the 1st line chemotherapy for esophageal cancer?

Symposium 19
Optimal Treatment Strategy for Head and Neck Cancer in the Era of Immunotherapy – Current Evidence and Future Directions –

Symposium 20
Evidence and Practice of Advance Care Planning

Symposium 21
How to support elderly cancer patients through multidisciplinary collaboration

Symposium 22
New molecular target therapies based on genome sequencing

Symposium 23
Future perspective of antibody-drug conjugate (ADC) for various cancer

Symposium 24
Hope and future: perspectives on complex innovative design

Symposium 25
Tumor-agnostic clinical questions in the recent medical oncology field

Symposium 26
Immune and cell therapy for hematologic malignancies

Symposium 27
Perioperative treatment reloaded: role of immune checkpoint inhibitors and targeted therapies

Symposium 28
Future Prospects for Treatment of Cancer Cachexia

Symposium 29
Essence of Guidelines for Psychiatric Symptoms in Cancer Care

ASCO/JSMO Joint Symposium
Emerging novel therapy (including new generation CAR-T, BiTE, cancer RNA vaccine)

ESMO/JSMO Joint Symposium
Cutting-edge precision oncology (including ctDNA/RNA, WGS/WES, multi-omics analyses)

Asia-Pacific/JSMO Joint Symposium
Digital transformation in clinical practice and trials (including telemedicine, eConsent/ePRO)

DIA/JSMO Joint Symposium
Novel International Clinical Research Design and its Regulation

SIOG/JSMO Joint Symposium
Current and Future of Financial Toxicity

Joint Symposium 1
Cancer Genomic Medicine and Beyond

Joint Symposium 2
Symptom Management of Bone Metastases

Joint Symposium 3
New developments in targeted radionuclide therapy

Joint Symposium 4
Anti-cancer medicine and cardiovascular adverse events

Joint Symposium 5
Tips for genetic medicine encountered in precision oncology

Joint Symposium 6
Implementing Patients' Voices to the Field: Challenges and Future of Qualitative Research

Committee Program 1
JSMO Committee on Public Information and Negotiation Program

Committee Program 2
Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region

Committee Program 3
Overview of Oncocardiology guideline

Committee Program 4
Part1:Overview of JSMO Cancer Immunotherapy Guideline, Third Edition

Committee Program 4
Part2: Molecular Testing for Colorectal Cancer Treatment: Key points of the revision